Obalon Therapeutics, Inc. Prices $3,000,000 Registered Direct Offering
The company has retained A.G.P./
This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-221264) previously filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
To the extent that statements contained in this press release are not descriptions of historical facts regarding
Chief Financial Officer
Office: +1 760 607 5103
Source: Obalon Therapeutics, Inc.